Catalent (CTLT)
(Delayed Data from NYSE)
$60.00 USD
-0.11 (-0.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.97 -0.03 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth D Momentum B VGM
Company Summary
Somerset, NJ-based Catalent, Inc. is a global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Catalent operates through two arms following the change in its organizational structure — Pharma and Consumer Health (PCH) segment (consolidating the prior Softgel & Oral Technologies, Oral & Specialty Delivery and Clinical Supply Services segments) and Biologics.
Biologics (45% of aggregate revenues in FY 2024, down 2% at constant exchange rate or CER from FY 2023): The segment provides formulation, development, and manufacturing for ...
Company Summary
Somerset, NJ-based Catalent, Inc. is a global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Catalent operates through two arms following the change in its organizational structure — Pharma and Consumer Health (PCH) segment (consolidating the prior Softgel & Oral Technologies, Oral & Specialty Delivery and Clinical Supply Services segments) and Biologics.
Biologics (45% of aggregate revenues in FY 2024, down 2% at constant exchange rate or CER from FY 2023): The segment provides formulation, development, and manufacturing for biologic proteins, cell, gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. Representative customers of the segment include Halozyme and Moderna, along with a broad range of innovative small and mid-tier biopharmaceutical customers. Offerings include the GPEx suite of technologies, SMARTag next-generation ADC technology, OneBio Integrated Suite and UpTempo AAV platform. The clinical supply services business provides a global network for clinical distribution, as well as labeling, packaging, and cold-chain storage for clinical trials and commercial supply of biotherapeutics and cell and gene therapies. The fill and finish services are largely focused on complex pharmaceuticals and biologics. The segment also offers analytical development and testing services for proteins, gene and cell therapies, and other biologic modalities, including bioassay.
PCH (55%, up 5%): The PCH segment encompasses the offerings of three of the company's prior reportable segments — Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services — and comprises Catalent’s capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. Representative customers include GlaxoSmithKline and Pfizer.
General Information
Catalent, Inc
14 SCHOOLHOUSE ROAD
SOMERSET, NJ 08873
Phone: 732-537-6200
Fax: 732-537-6480
Email: investors@catalent.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | June |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/20/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.10 |
Current Year EPS Consensus Estimate | 1.21 |
Estimated Long-Term EPS Growth Rate | 30.10 |
Exp Earnings Date | 11/20/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 60.11 |
52 Week High | 61.20 |
52 Week Low | 31.80 |
Beta | 1.15 |
20 Day Moving Average | 1,697,627.00 |
Target Price Consensus | 62.36 |
4 Week | 0.94 |
12 Week | 6.70 |
YTD | 33.54 |
4 Week | -0.26 |
12 Week | 2.18 |
YTD | 11.70 |
Shares Outstanding (millions) | 181.46 |
Market Capitalization (millions) | 10,887.82 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 49.69 |
Trailing 12 Months | 240.00 |
PEG Ratio | 1.65 |
vs. Previous Year | 533.33% |
vs. Previous Quarter | 480.00% |
vs. Previous Year | 21.82% |
vs. Previous Quarter | 21.14% |
Price/Book | 3.01 |
Price/Cash Flow | 22.87 |
Price / Sales | 2.48 |
6/30/24 | -0.56 |
3/31/24 | -2.73 |
12/31/23 | -2.43 |
6/30/24 | -0.21 |
3/31/24 | -1.06 |
12/31/23 | -0.98 |
6/30/24 | 2.52 |
3/31/24 | 2.51 |
12/31/23 | 2.48 |
6/30/24 | 1.96 |
3/31/24 | 1.77 |
12/31/23 | 1.73 |
6/30/24 | -0.47 |
3/31/24 | -2.59 |
12/31/23 | -2.48 |
6/30/24 | -22.72 |
3/31/24 | -26.61 |
12/31/23 | -29.91 |
6/30/24 | -23.44 |
3/31/24 | -29.89 |
12/31/23 | -34.91 |
6/30/24 | 19.91 |
3/31/24 | 19.95 |
12/31/23 | 20.41 |
6/30/24 | 4.75 |
3/31/24 | 4.34 |
12/31/23 | 4.35 |
6/30/24 | 1.35 |
3/31/24 | 1.37 |
12/31/23 | 1.34 |
6/30/24 | 57.40 |
3/31/24 | 57.74 |
12/31/23 | 57.36 |